Table 1.

Patient characteristics

Parental trial population (n = 312)Biomarker population (n = 181)
n (%)n (%)
Age, years
 Median (range)57 (32–76)57 (32–76)
 <55 years136 (43)83 (46)
 ≥55 years176 (56)98 (54)
Baseline ECOG performance status
 0163 (52)96 (53)
 1149 (48)85 (47)
Hormone receptor status
 Positive265 (85)159 (88)
 Negative47 (15)22 (12)
HER2-negative disease309 (99)181 (100)
Measurable disease
 Yes268 (86)162 (90)
 No44 (14)19 (10)
Disease-free interval
 ≤24 months102 (33)59 (33)
 >24 monthsa210 (67)122 (67)
Distant metastases at initial diagnosis
 Yes42 (13)25 (14)
 No270 (87)156 (86)
Sites of metastatic disease
 Lung metastases94 (30)61 (34)
 Liver metastases180 (58)112 (62)
 Bone-only disease25 (8)10 (6)
No. of metastatic sites
 151 (16)23 (13)
 2123 (40)64 (35)
 ≥3137 (44)94 (52)
Prior hormonal therapy
 Primary breast cancer157 (50)94 (52)
 Metastatic breast cancer151 (48)88 (49)
Prior (neo)adjuvant chemotherapy178 (57)103 (57)
  • aDisease-free interval was defined as the period from primary breast cancer diagnosis to first relapse.